ROQA.F logo

Roquefort Therapeutics OTCPK:ROQA.F Stock Report

Last Price

US$0.05

Market Cap

US$6.2m

7D

0%

1Y

n/a

Updated

26 Nov, 2024

Data

Company Financials

Roquefort Therapeutics plc

OTCPK:ROQA.F Stock Report

Market Cap: US$6.2m

ROQA.F Stock Overview

A material biotech company, engages in the development of medicines for the treatment of cancer. More details

ROQA.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Roquefort Therapeutics plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Roquefort Therapeutics
Historical stock prices
Current Share PriceUK£0.05
52 Week HighUK£0.10
52 Week LowUK£0.049
Beta-0.31
11 Month Change0%
3 Month Changen/a
1 Year Changen/a
33 Year Changen/a
5 Year Changen/a
Change since IPO-58.33%

Recent News & Updates

Recent updates

Shareholder Returns

ROQA.FUS BiotechsUS Market
7D0%4.0%2.2%
1Yn/a18.3%32.6%

Return vs Industry: Insufficient data to determine how ROQA.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how ROQA.F performed against the US Market.

Price Volatility

Is ROQA.F's price volatile compared to industry and market?
ROQA.F volatility
ROQA.F Average Weekly Movementn/a
Biotechs Industry Average Movement9.8%
Market Average Movement6.3%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: ROQA.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ROQA.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
202010Ajan Reginaldwww.roquefortplc.com

Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy, toxicology studies, and orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and natural killer cell-mediated anti-cancer action. The company was incorporated in 2020 and is based in London, the United Kingdom.

Roquefort Therapeutics plc Fundamentals Summary

How do Roquefort Therapeutics's earnings and revenue compare to its market cap?
ROQA.F fundamental statistics
Market capUS$6.16m
Earnings (TTM)-US$1.93m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ROQA.F income statement (TTM)
RevenueUK£0
Cost of RevenueUK£16.00k
Gross Profit-UK£16.00k
Other ExpensesUK£1.53m
Earnings-UK£1.54m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.012
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio12.4%

How did ROQA.F perform over the long term?

See historical performance and comparison